Argus raised the firm’s price target on Biogen to $320 from $315 and keeps a Buy rating on the shares. The company’s MS drug Tecfidera has seen weaker results in recent quarters due to competition from new generic drugs and challenges in other parts of its portfolio, but one of its other potential Alzheimer’s treatments, lecanemab, has proven more successful in clinical trials and is now being evaluated for potential approval in multiple markets, the analyst tells investors in a research note. The firm is cutting its 2023 EPS view on Biogen to $15.60 from $16.40, reflecting the management’s guidance and the decline in revenue from multiple sclerosis drugs, but it also expects growth to resume in 2024 as the company launches new products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biogen upgraded to Overweight from Neutral at Piper Sandler
- Truist biotechnology analyst to hold an analyst/industry conference call
- Biogen exercises option with Denali to develop its ATV:ABeta program
- Biogen price target lowered to $349 from $351 at Morgan Stanley
- Biogen price target lowered to $307 from $310 at Barclays